MedTrace Logo

Post Market Clinical Follow-Up KeriFuse®

NCT06546332 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2025-09-11

No results posted yet for this study

Summary

The general objective of this study is to evaluate the performances and the safety related to the KeriFuse® intramedullary arthrodesis implant and associated instrumentation used in accordance with their approved labelling and instruction for use. Performance and safety of KeriFuse® intramedullary arthrodesis implant will be established on short and middle-terms in regards to the implant life-cycle.

Conditions

Interventions

DEVICE

KeriFuse®

The intramedullary arthrodesis Implant (KeriFuse®) is indicated for consolidation or bone fusion (arthrodesis) of degraded or arthritic distal interphalangeal (DIP) of hand digits or interphalangeal (IP) joint of the hand thumb.

Sponsors & Collaborators

  • Keri Medical SA

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2025-12-31
Completion
2027-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06546332 on ClinicalTrials.gov